Verve Therapeutics Is Maintained at Outperform by RBC Capital

Dow JonesMar 4 10:53 ET · Ratings

RBC Capital Maintains Verve Therapeutics(VERV.US) With Buy Rating, Cuts Target Price to $15

Moomoo NewsMar 4 07:34 ET · Ratings

RBC Cuts Price Target on Verve Therapeutics to $15 From $17, Keeps Outperform, Speculative Risk

MT NewswiresMar 4 07:05 ET · Ratings

Express News | Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersMar 3 16:05 ET

Verve Therapeutics, Inc. (NASDAQ:VERV) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Simply Wall StMar 3 05:02 ET

Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verve TherapeuticsMar 3 00:00 ET